PL3525799T3 - Sposób ustanawiania, przywracania i utrzymywania homeostazy powierzchni oka - Google Patents

Sposób ustanawiania, przywracania i utrzymywania homeostazy powierzchni oka

Info

Publication number
PL3525799T3
PL3525799T3 PL17817868T PL17817868T PL3525799T3 PL 3525799 T3 PL3525799 T3 PL 3525799T3 PL 17817868 T PL17817868 T PL 17817868T PL 17817868 T PL17817868 T PL 17817868T PL 3525799 T3 PL3525799 T3 PL 3525799T3
Authority
PL
Poland
Prior art keywords
restoring
establishing
ocular surface
homeostasis
preserving
Prior art date
Application number
PL17817868T
Other languages
English (en)
Inventor
Wolfgang Georg Konrad Muller-Lierheim
Gysbert-Botho Van Setten
Original Assignee
i.com medical GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60766004&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3525799(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by i.com medical GmbH filed Critical i.com medical GmbH
Publication of PL3525799T3 publication Critical patent/PL3525799T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PL17817868T 2016-10-14 2017-10-02 Sposób ustanawiania, przywracania i utrzymywania homeostazy powierzchni oka PL3525799T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662408559P 2016-10-14 2016-10-14
US201762516911P 2017-06-08 2017-06-08
PCT/IB2017/001364 WO2018069763A1 (en) 2016-10-14 2017-10-02 Method for establishing, restoring, and preserving homeostasis of the ocular surface
EP17817868.7A EP3525799B1 (en) 2016-10-14 2017-10-02 Method for establishing, restoring, and preserving homeostasis of the ocular surface

Publications (1)

Publication Number Publication Date
PL3525799T3 true PL3525799T3 (pl) 2022-05-16

Family

ID=60766004

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17817868T PL3525799T3 (pl) 2016-10-14 2017-10-02 Sposób ustanawiania, przywracania i utrzymywania homeostazy powierzchni oka

Country Status (8)

Country Link
US (1) US20190240251A1 (pl)
EP (2) EP3525799B1 (pl)
JP (3) JP2019532105A (pl)
KR (1) KR20190068575A (pl)
ES (1) ES2909998T3 (pl)
HU (1) HUE058672T2 (pl)
PL (1) PL3525799T3 (pl)
WO (1) WO2018069763A1 (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3525799B1 (en) 2016-10-14 2022-01-26 i.com Medical GmbH Method for establishing, restoring, and preserving homeostasis of the ocular surface
WO2019202017A1 (en) * 2018-04-18 2019-10-24 i.com medical GmbH High molecular weight hyaluronic acid for treatment and prevention of severe ocular surface disease
WO2020057548A1 (en) * 2018-09-20 2020-03-26 The Hong Kong University Of Science And Technology Eyedrop compositions
WO2020157570A1 (en) * 2019-01-31 2020-08-06 i.com medical GmbH Hyaluronic acid for relief of idiopathic ocular pain
CN116096355A (zh) * 2020-06-12 2023-05-09 I.Com医疗有限责任公司 用于治疗角膜神经损伤或损失的高分子量透明质酸
JP7828519B2 (ja) * 2020-06-21 2026-03-12 アイ．コム メディカル ゲーエムベーハー 高分子量ヒアルロン酸の眼科用薬物輸送ビヒクルとしての使用
CA3258421A1 (en) * 2022-06-08 2023-12-14 Aramis Biosciences, Inc. METHODS OF TREATING DRY EYE DISEASE
EP4591860A1 (en) * 2024-01-23 2025-07-30 FB Vision S.p.A. Ophthalmic pharmaceutical composition for the prevention and treatment of dry eye syndrome

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1263606A (en) * 1985-05-29 1989-12-05 Jeffrey P. Gilbard Non-toxic opthalmic preparations
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
JP3050898B2 (ja) * 1990-07-06 2000-06-12 千寿製薬株式会社 水性医薬製剤
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
IT1277707B1 (it) * 1995-12-22 1997-11-11 Chemedica Sa Formulazione oftalmica a base di ialuronato di sodio per uso nella chirurgia oculare
SE9700827D0 (sv) * 1997-03-07 1997-03-07 Pharmacia & Upjohn Ab Ophthalmic composition
ATE250924T1 (de) * 2000-04-07 2003-10-15 Medidom Lab Cyklosporin, hyaluronsäure und polysorbate enthaltenes augenarzneimittel
US6528464B1 (en) * 2001-08-17 2003-03-04 Bausch & Lomb Incorporated Composition and method for inhibiting uptake of biguanide antimicrobials by hydrogels
JP3779200B2 (ja) * 2001-11-28 2006-05-24 電気化学工業株式会社 ヒアルロン酸及び／又はその塩の水溶液の安定化組成物
DE10161149B4 (de) * 2001-12-12 2007-03-08 Ursapharm Arzneimittel Gmbh & Co. Kg Verwendung von Heparin-haltigem Ophthalmikum
EP1539193A4 (en) * 2002-07-03 2010-05-05 Pericor Science Inc HYALURONIC ACID COMPOSITIONS AND METHODS OF USE
DE10360425A1 (de) 2003-12-19 2005-07-28 Ursapharm Arzneimittel Gmbh & Co. Kg Verwendung von Hyaluronsäure, Hyaluronat und/oder deren Derivate zur Herstellung einer pharmazeutischen Zusammensetzung
US20080306022A1 (en) * 2005-10-12 2008-12-11 Kenji Miyamoto Agent for Applying to Mucosa and Method for the Production Thereof
JP2008255061A (ja) * 2007-04-06 2008-10-23 Shiseido Co Ltd 可溶性架橋ヒアルロン酸含有眼用組成物
US10105441B2 (en) * 2007-08-16 2018-10-23 The Schepens Eye Research Institute, Inc. Method for inhibiting or reducing dry eye disease by IL-1Ra
KR20110020819A (ko) * 2008-05-15 2011-03-03 가부시키가이샤 아루떼꾸 우에노 안구건조증 및/또는 각막/결막 질환 치료용 약학 조성물
JP5595206B2 (ja) * 2009-09-30 2014-09-24 ロート製薬株式会社 眼科用液体組成物
US8283463B2 (en) * 2010-02-09 2012-10-09 Bausch & Lomb Incorporated Sterile hyaluronic acid solutions
CN107337735B (zh) * 2010-07-29 2021-06-22 巴扎德制药公司 嵌合il-1受体i型激动剂和拮抗剂
PH12013500424B1 (en) * 2010-09-10 2018-07-11 Santen Pharmaceutical Co Ltd Agent for treatment of dry eye characterized by combining p2y2 receptor agonist and hyaluronic acid or salt thereof, method for treating dry eye, and use of the p2y2 receptor agonist and hyaluronic acid or salt thereof
SG11201703572SA (en) * 2014-12-02 2017-05-30 Regeneron Pharma Animal model for dry eye and methods of use of such animals
SG10201901426WA (en) * 2015-03-06 2019-03-28 Santen Pharmaceutical Co Ltd Ophthalmic composition
US20170014339A1 (en) 2015-07-17 2017-01-19 i.com medical GmbH Tear Substitute, Fluid for Being Used as a Tear Substitute, and Method for Producing a Tear Substitute
EP3525799B1 (en) 2016-10-14 2022-01-26 i.com Medical GmbH Method for establishing, restoring, and preserving homeostasis of the ocular surface
WO2019202017A1 (en) * 2018-04-18 2019-10-24 i.com medical GmbH High molecular weight hyaluronic acid for treatment and prevention of severe ocular surface disease
WO2020157570A1 (en) * 2019-01-31 2020-08-06 i.com medical GmbH Hyaluronic acid for relief of idiopathic ocular pain

Also Published As

Publication number Publication date
EP3871682A1 (en) 2021-09-01
HUE058672T2 (hu) 2022-09-28
EP3525799A1 (en) 2019-08-21
EP3525799B1 (en) 2022-01-26
US20190240251A1 (en) 2019-08-08
KR20190068575A (ko) 2019-06-18
ES2909998T3 (es) 2022-05-11
JP2025029084A (ja) 2025-03-05
WO2018069763A1 (en) 2018-04-19
JP2022153583A (ja) 2022-10-12
JP2019532105A (ja) 2019-11-07

Similar Documents

Publication Publication Date Title
IL266596A (en) Causes, uses and methods of treating synovialitis
PL3525799T3 (pl) Sposób ustanawiania, przywracania i utrzymywania homeostazy powierzchni oka
IL254533A0 (en) Systems and methods for heart valve therapy
IL256501B (en) Causes, uses and methods of treating synuclein pathology
IL269490B (en) Surface treatment methods and compositions therefor
EP3151797A4 (en) Methods and devices for treating the skin
EP3500289A4 (en) METHODS OF TREATING TRACHEOBRONCHOMALACIA
PL3648595T3 (pl) Sposób konserwacji pyłku
SG11201801790UA (en) Polishing liquid, polishing liquid set, and substrate polishing method
EP3252124A4 (en) Surface treatment agent
SG10202003053VA (en) Deactivation wipe kit and method of forming and using the same
SG11202001013YA (en) Polishing liquid, polishing liquid set and polishing method
PL3519142T3 (pl) Sposób obróbki powierzchniowej przedmiotu
EP3484515A4 (en) METHOD FOR TREATING FIBROSE
IL271728A (en) Materials, uses and treatment methods
EP3375568A4 (en) Surface treatment device and surface treatment method
PT3430883T (pt) Aparelho de varejar, particularmente para varejar oliveiras e semelhantes
SG11202002314WA (en) Polishing solution, polishing solution set, and polishing method
EP3551027B8 (en) Machine for the drying of dishes or the like and method for the drying of dishes or the like with said machine.
EP3219787A4 (en) Agent for preserving biological component, and method for recovering biological component
EP3176149A4 (en) Method for improving preservation stability of 2,2-difluoroacetoaldehyde
PT3350150T (pt) 1,1-difeniletilenos substituídos por alcenilfenoxilo, processos para a sua preparação e sua utilização
TWI561676B (en) Aqueous metal surface treatment agent and metal surface treatment method using the same
EP3423063A4 (en) COMPOSITIONS AND METHODS FOR TREATING SEARCH OR SUBSTANCE ABUSE MISTAKES
PT3585985T (pt) Método de conservação